ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Amphetamine

Also written as “ADZENYS XR-ODT”, “Amphetamine Sulfate” and “Amphetamine Extended Release (ER) Tablet 20 mg”.

Its studies are mostly in Attention Deficit Disorder with Hyperactivity, led by 3 companies.

Drug pageAmphetamine: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 23, 20186 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tris Pharmaits history only30 open or runningphase 4since Jul 23, 2018Mar 9, 2017none ahead
Azurity Pharmaceuticalsits history only20 open or runningphase 4since Nov 11, 2013Nov 11, 2013none ahead
Aytu BioPharma10 open or runningphase 4since Sep 5, 2025Sep 5, 2025none ahead

Also a collaborator on its studies: Takeda.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Aytu BioPharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 5, 2025First study: phase 4 study in Attention Deficit Disorder with HyperactivityFirst studyNCT07169162 · United States

TargetBeta

“Dopamine transporter releasing agent; Dopamine transporter releasing agent; Dopamine transporter releasing agent; Dopamine transporter releasing agent”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
lisdexamfetamineruleTakedaphase 447
BupropionruleGlaxoSmithKlinephase 429
dexmethylphenidaterulecingulate-therapeuticsphase 414

Studies

The one study Aytu BioPharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07169162Attention Deficit Disorder with Hyperactivity · United States4WithdrawnSep 5, 20250

How it is read

Names in the registry

  • “ADZENYS XR-ODT”, 1 entry
  • “Amphetamine Sulfate”, 1 entry
  • “Amphetamine Extended Release (ER) Tablet 20 mg”, 1 entry
  • “Amphetamine + SPD503”, 1 entry
  • “Amphetamine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.